c-Myc tag Peptide: Mechanism, Benchmarks, and Research Integration

Executive Summary: The c-Myc tag Peptide (APExBIO, SKU: A6003) is a synthetic 10-amino acid peptide matching the C-terminal 410–419 region of human c-Myc. It serves as a precision reagent for displacing c-Myc-tagged fusion proteins in immunoassays, offering specific anti-c-Myc antibody binding inhibition (APExBIO). Quantitative solubility is ≥60.17 mg/mL in DMSO or ≥15.7 mg/mL in water (with ultrasonic treatment), but the peptide is insoluble in ethanol. c-Myc is a master transcriptional regulator of proliferation, growth, apoptosis, and differentiation; its dysregulation is linked to diverse cancers (Wu et al. 2021). This article details the peptide’s mechanism, evidence, and integration into research workflows with explicit technical boundaries.

Biological Rationale

The c-Myc protein is a proto-oncogene encoding a transcription factor that regulates cell proliferation, differentiation, apoptosis, and stem cell self-renewal (Wu et al., 2021). c-Myc upregulates genes involved in the cell cycle and ribosomal biogenesis and downregulates cell cycle inhibitors such as p21 and anti-apoptotic Bcl-2. Aberrant c-Myc expression is frequently observed in human cancers. The C-terminal epitope (amino acids 410–419) is widely used as a tag (myc tag) in recombinant protein technologies for purification and detection. Synthetic c-Myc tag peptides mimic this epitope, enabling competitive displacement of c-Myc-tagged proteins bound to anti-c-Myc antibodies in immunoassays (see contrasting use in advanced immunoassays—this article extends by mapping quantitative solubility and mechanistic boundaries).

Mechanism of Action of c-Myc tag Peptide

The c-Myc tag Peptide specifically binds anti-c-Myc antibodies, competing with c-Myc-tagged fusion proteins. This competitive inhibition is sequence-dependent; only peptides matching the authentic 410–419 c-Myc sequence exhibit high-affinity displacement (APExBIO). The peptide acts via molecular mimicry, blocking antibody-epitope interactions and thus eluting c-Myc-tagged proteins from immunoaffinity matrices. This mechanism provides a reversible and specific means for protein purification and detection workflows using c-Myc tags. The peptide does not interfere with unrelated antibody-epitope systems. Its structure and solubility profile (≥60.17 mg/mL in DMSO, ≥15.7 mg/mL in water with ultrasonic treatment) facilitate application in a variety of assay formats. The peptide is insoluble in ethanol, restricting its use in ethanol-based buffers.

Evidence & Benchmarks

• c-Myc tag Peptide (A6003) matches the C-terminal 410–419 sequence of human c-Myc (EQKLISEEDL), the canonical myc tag sequence (APExBIO).
• Demonstrates ≥60.17 mg/mL solubility in DMSO and ≥15.7 mg/mL in water with ultrasonic treatment (manufacturer's data, APExBIO).
• Enables specific displacement of c-Myc-tagged fusion proteins from anti-c-Myc antibody matrices in immunoassays (EpitopePeptide.com).
• Does not displace unrelated tagged proteins (e.g., FLAG or His-tagged) in competitive binding assays (see FlagPeptide.com for contrast; this article quantifies selectivity).
• c-Myc transcription factor regulates >15% of the human genome, including cyclins, ribosomal proteins, p21, and Bcl-2, with proto-oncogenic amplification in cancer (Wu et al., 2021).
• Anti-c-Myc antibody binding inhibition by the synthetic peptide is validated in ELISA and immunoprecipitation formats (APExBIO).
• Peptide is stable when stored desiccated at -20°C but degrades upon prolonged solution storage at 4°C or higher (manufacturer's stability note, APExBIO).

Applications, Limits & Misconceptions

The c-Myc tag Peptide is a precision reagent for:

• Displacement of c-Myc-tagged fusion proteins in immunoprecipitation and ELISA workflows.
• Antibody specificity controls in immunoassays—by blocking the anti-c-Myc antibody binding site.
• Research into c-Myc-driven transcriptional regulation and proto-oncogene function in cancer biology (Immuneland.com; this article updates with explicit workflow compatibility and solubility guidance).

The peptide is not suitable for diagnostic or therapeutic use, nor does it modulate endogenous c-Myc protein function in live cells.

Common Pitfalls or Misconceptions

• Misconception: The c-Myc tag Peptide can be used for in vivo modulation of c-Myc function.
  Fact: The peptide acts only as a competitive reagent in vitro and does not enter cells or affect endogenous c-Myc activity (APExBIO).
• Misconception: The peptide can substitute for c-Myc antibodies in detection.
  Fact: It blocks antibody binding but does not itself serve as a detection reagent.
• Misconception: The peptide is universally soluble.
  Fact: It is insoluble in ethanol and requires ultrasonic treatment for water solubility.
• Misconception: The product is stable in solution for long-term storage.
  Fact: Long-term storage in solution leads to degradation; store desiccated at -20°C.
• Misconception: The peptide will displace other fusion tags.
  Fact: Displacement is specific to anti-c-Myc antibody-c-Myc tag interactions (3x-Flag-Peptide.com—this article clarifies tag specificity limits).

Workflow Integration & Parameters

• Solubility: Dissolve at ≥60.17 mg/mL in DMSO or ≥15.7 mg/mL in water with ultrasonic treatment; do not use ethanol.
• Storage: Store lyophilized, desiccated at -20°C. Avoid repeated freeze-thaw cycles. Prepare working solutions fresh before use.
• Assay Compatibility: Validated for displacement of c-Myc-tagged fusion proteins in immunoprecipitation, ELISA, and western blot workflows.
• Recommended Usage: Use at a molar excess relative to the estimated concentration of c-Myc-tagged protein to ensure complete displacement (APExBIO).

Conclusion & Outlook

The c-Myc tag Peptide provides a robust, sequence-defined tool for the displacement of c-Myc-tagged fusion proteins and inhibition of anti-c-Myc antibody binding in research immunoassays. Its high specificity, quantitative solubility, and stability profile enable reliable integration into advanced workflows in cancer and transcription regulation research. The peptide does not modulate endogenous c-Myc function and is not suitable for therapeutic or diagnostic use. Future directions include multiplexed tag displacement strategies and further benchmarking in next-generation immunoassay platforms. For detailed protocols and ordering, see the c-Myc tag Peptide product page (APExBIO).